Literature DB >> 28409247

[Cetuximab plus chemoradiotherapy for anal carcinoma in immunocompetent patients does not change existing therapy standards : Results from the prospective, multicenter E3205 trial].

Carsten Nieder1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28409247     DOI： 10.1007/s00066-017-1133-x

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  6 in total

1.  Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205).

Authors:  Madhur K Garg; Fengmin Zhao; Joseph A Sparano; Joel Palefsky; Richard Whittington; Edith P Mitchell; Mary F Mulcahy; Karin I Armstrong; Nassim H Nabbout; Shalom Kalnicki; Bassel F El-Rayes; Adedayo A Onitilo; Daniel J Moriarty; Thomas J Fitzgerald; Al B Benson
Journal:  J Clin Oncol       Date:  2017-01-09       Impact factor: 44.544

2.  Significance of Co-expression of Epidermal Growth Factor Receptor and Ki67 on Clinical Outcome in Patients With Anal Cancer Treated With Chemoradiotherapy: An Analysis of NRG Oncology RTOG 9811.

Authors:  Corinne M Doll; Jennifer Moughan; Alexander Klimowicz; Clement K Ho; Elizabeth N Kornaga; Susan P Lees-Miller; Jaffer A Ajani; Christopher H Crane; Lisa A Kachnic; Gordon S Okawara; Lawrence B Berk; Kevin S Roof; Mark J Becker; David L Grisell; Robert J Ellis; Paul W Sperduto; Gerald W Marsa; Chandan Guha; Anthony M Magliocco
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-11-23       Impact factor: 7.038

3.  Implementing Intensity-modulated Radiotherapy with Simultaneous Integrated Boost for Anal Cancer: 3 Year Outcomes at Two Sydney Institutions.

Authors:  A Yates; S Carroll; A Kneebone; R Tse; L Horvath; C Byrne; M Solomon; G Hruby
Journal:  Clin Oncol (R Coll Radiol)       Date:  2015-09-14       Impact factor: 4.126

4.  Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin.

Authors:  Leonard L Gunderson; Kathryn A Winter; Jaffer A Ajani; John E Pedersen; Jennifer Moughan; Al B Benson; Charles R Thomas; Robert J Mayer; Michael G Haddock; Tyvin A Rich; Christopher G Willett
Journal:  J Clin Oncol       Date:  2012-11-13       Impact factor: 44.544

5.  Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.

Authors:  Roger D James; Robert Glynne-Jones; Helen M Meadows; David Cunningham; Arthur Sun Myint; Mark P Saunders; Timothy Maughan; Alec McDonald; Sharadah Essapen; Martin Leslie; Stephen Falk; Charles Wilson; Simon Gollins; Rubina Begum; Jonathan Ledermann; Latha Kadalayil; David Sebag-Montefiore
Journal:  Lancet Oncol       Date:  2013-04-09       Impact factor: 41.316

6.  Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial.

Authors:  Robert Glynne-Jones; David Sebag-Montefiore; Helen M Meadows; David Cunningham; Rubina Begum; Fawzi Adab; Kim Benstead; Robert J Harte; Jill Stewart; Sandy Beare; Allan Hackshaw; Latha Kadalayil
Journal:  Lancet Oncol       Date:  2017-02-11       Impact factor: 41.316
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.